MD Anderson Collaborated with Radiopharm Theranostics to Launch Joint Venture for Novel Radiopharmaceuticals Therapies
Shots:
- MD Anderson and Radiopharm Theranostics collaborated to launch Radiopharm Ventures, a JV to develop novel radiopharmaceutical therapeutic for cancer
- The collaboration will use MD Anderson’s innovative and proprietary technologies in Ag discovery and molecular imaging with Radiopharm’s expertise in developing radiopharmaceutical products. The joint venture's initial area of focus on four therapeutic solutions will be based on MD Anderson's intellectual property
- Radiopharm Ventures gets the right to select additional targets to prioritize selection based on unmet needs in oncology. In preclinical studies, B7-H3 was effective in eliminating resistant colorectal cancers in laboratory models
Ref: MD Anderson | Image: MD Anderson
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
